2021
Brief report: Cannabis and opioid use disorder among heart failure admissions, 2008–2018
Chouairi F, Mullan CW, Ravindra N, Clark KAA, Jaffe EM, Bhinder J, Fuery M, Guha A, Ahmad T, Desai NR. Brief report: Cannabis and opioid use disorder among heart failure admissions, 2008–2018. PLOS ONE 2021, 16: e0255514. PMID: 34591847, PMCID: PMC8483306, DOI: 10.1371/journal.pone.0255514.Peer-Reviewed Original ResearchCannabis use disorder among atrial fibrillation admissions, 2008–2018
Chouairi F, Miller PE, Guha A, Clarke J, Reinhardt SW, Ahmad T, Freeman JV, Desai NR, Friedman DJ. Cannabis use disorder among atrial fibrillation admissions, 2008–2018. Pacing And Clinical Electrophysiology 2021, 44: 1934-1938. PMID: 34506639, DOI: 10.1111/pace.14356.Peer-Reviewed Original ResearchConceptsAtrial fibrillation hospitalizationsAF hospitalizationsImpact of CUDNational Inpatient SampleProportion of admissionsDiseases diagnosis codesPrevalence of cannabisHistory of CUDHospital dischargeYounger patientsHigher proportionUnderserved patientsBlack raceDiagnosis codesInpatient SampleInternational ClassificationHospitalizationLegality of cannabisCannabis usePatientsAdmissionCodiagnosisLittle dataCUDCannabisEvaluation of Racial and Ethnic Disparities in Cardiac Transplantation
Chouairi F, Fuery M, Clark KA, Mullan CW, Stewart J, Caraballo C, Clarke J, Sen S, Guha A, Ibrahim NE, Cole RT, Holaday L, Anwer M, Geirsson A, Rogers JG, Velazquez EJ, Desai NR, Ahmad T, Miller PE. Evaluation of Racial and Ethnic Disparities in Cardiac Transplantation. Journal Of The American Heart Association 2021, 10: e021067. PMID: 34431324, PMCID: PMC8649228, DOI: 10.1161/jaha.120.021067.Peer-Reviewed Original ResearchConceptsWhite patientsHispanic patientsBlack patientsCardiac transplantationHeart transplantationHigh riskEthnic disparitiesAdult heart recipientsAllocation system changePost-transplant deathPost-transplant mortalityOrgan Sharing databasePost-transplantation deathNew allocation systemHeart recipientsDiabetes mellitusRenal diseaseSharing databaseTransplantation ratesUnited NetworkContemporary outcomesPatientsTransplantationDonor characteristicsStudy periodComparison of Transcatheter and Open Mitral Valve Repair Among Patients With Mitral Regurgitation
Kay B, Chouairi F, Clark KAA, Reinhardt SW, Fuery M, Guha A, Ahmad T, Kaple RK, Desai NR. Comparison of Transcatheter and Open Mitral Valve Repair Among Patients With Mitral Regurgitation. Mayo Clinic Proceedings 2021, 96: 1522-1529. PMID: 34088415, DOI: 10.1016/j.mayocp.2021.01.029.Peer-Reviewed Original ResearchConceptsMitral valve repairMitral regurgitationValve repairInternational ClassificationPatient underwent mitral valve repairOpen mitral valve repairUnderwent mitral valve repairTranscatheter mitral valve repairStudy periodComparison of transcatheterProhibitive surgical riskTenth Revision codesTotal hospital chargesDegenerative mitral regurgitationNational Inpatient SampleLength of stayTranscatheter mitral valve repair deviceDischarge homeHospital mortalityDischarge dispositionPatient comorbiditiesSurgical riskHospital chargesMedian lengthNinth RevisionDifferences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction
Daubert MA, Yow E, Barnhart HX, Piña IL, Ahmad T, Leifer E, Cooper L, Desvigne‐Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, O’Connor C, Felker GM. Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. Journal Of The American Heart Association 2021, 10: e019712. PMID: 33955231, PMCID: PMC8200692, DOI: 10.1161/jaha.120.019712.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiomarkersCanadaCause of DeathFemaleFollow-Up StudiesGuideline AdherenceHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisProtein PrecursorsRetrospective StudiesSex DistributionSex FactorsStroke VolumeUnited StatesConceptsReduced ejection fractionNT-proBNP responseGuideline-directed medical therapyGUIDE-IT trialHeart failureEjection fractionNT-proBNPPrognostic valuePg/mLHF hospitalizationMedical therapyEquivalent prognostic valueNT-proBNP reductionNT-proBNP valuesGreater prognostic valueNonischemic causesClinical characteristicsClinical outcomesImproved outcomesLandmark analysisPrognostic biomarkerTherapeutic goalsConclusions MenSecondary analysisWomenImpact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies
Chouairi F, Mullan CW, Sen S, Mori M, Fuery M, Elder RW, Lesse J, Norton K, Clark KA, Miller PE, Mulligan D, Formica R, Rogers JG, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T. Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. PLOS ONE 2021, 16: e0247789. PMID: 33651802, PMCID: PMC7924739, DOI: 10.1371/journal.pone.0247789.Peer-Reviewed Original ResearchConceptsCongenital heart diseaseAllocation system changeHeart allocation systemNew heart allocation policyNew heart allocation systemTransplantation of patientsOrgan Sharing databasePost-transplantation outcomesPost-transplant survivalTime of transplantationMechanical circulatory supportRate of transplantationNumber of patientsHeart allocation policyNew allocation systemStatus 1ACardiac transplantAdult patientsSharing databaseWaitlist survivalCirculatory supportClinical benefitCongenital cardiomyopathyUnited NetworkCHD patientsRelation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry)
Pareek M, Singh A, Vadlamani L, Eder M, Pacor J, Park J, Ghazizadeh Z, Heard A, Cruz-Solbes AS, Nikooie R, Gier C, Ahmed ZV, Freeman JV, Meadows J, Smolderen KGE, Lampert R, Velazquez EJ, Ahmad T, Desai NR. Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). The American Journal Of Cardiology 2021, 146: 99-106. PMID: 33539857, PMCID: PMC7849530, DOI: 10.1016/j.amjcard.2021.01.029.Peer-Reviewed Original ResearchConceptsCardiovascular risk factorsCoronavirus disease 2019Risk factorsHigher troponin TCardiovascular diseaseCardiovascular eventsHospitalized patientsLaboratory findingsMental statusDisease 2019Multivariable binary logistic regression analysisTroponin TMajor adverse cardiovascular eventsPre-existing cardiovascular diseaseHigher C-reactive proteinCOVID-19 positive patientsPredictors of MACEPrevious ventricular arrhythmiaUse of P2YAdverse cardiovascular eventsProspective cohort studyTertiary care centerC-reactive proteinBinary logistic regression analysisPoor prognostic marker
2020
Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Mezzacappa C, Ravindra NG, Caraballo C, Chouairi F, Miller PE, Clarke JD, Gruen J, Mori M, McCullough M, Mullan C, Geirsson A, Rogers JG, Anwer M, Desai N, Ahmad T. Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLOS ONE 2020, 15: e0242928. PMID: 33270648, PMCID: PMC7714148, DOI: 10.1371/journal.pone.0242928.Peer-Reviewed Original ResearchConceptsClinical trialsVentricular assist deviceExclusion criteriaLVAD recipientsAssist deviceReal-world settingClinical implicationsClinical trial exclusion criteriaHeart failure clinical trialsEnd-stage renal diseaseEnd-stage heart failureReal-world registryRetrospective cohort studyLandmark clinical trialsStage renal diseaseTrial exclusion criteriaRisk of deathStage heart failureRespiratory failureCohort studyPatient characteristicsHeart failurePatient factorsRenal diseaseClinical outcomesImpact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement
Stawiarski K, Agboola O, Park J, Geirsson A, Jacoby D, Bellumkonda L, Ahmad T, Chou J, Lee F, Mangi A, Bonde P. Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement. ASAIO Journal 2020, 67: 650-657. PMID: 33074860, DOI: 10.1097/mat.0000000000001289.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHeart FailureHeart-Assist DevicesHumansLymphopeniaMaleMiddle AgedProportional Hazards ModelsConceptsAbsolute lymphocyte countCause mortalityLymphopenia groupLeft ventricular assist device patientsVentricular assist device patientsVentricular assist device placementCox proportional hazards modelImpact of lymphopeniaHeart failure populationKaplan-Meier plotsFurther clinical investigationProportional hazards modelLog-rank statisticsDurable LVADPreoperative lymphopeniaLVAD placementLymphocyte countLymphopenic patientsDevice patientsSingle centerPoor outcomePrognostic implicationsALC levelsFailure populationStudy populationCOVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system
Caraballo C, McCullough M, Fuery MA, Chouairi F, Keating C, Ravindra NG, Miller PE, Malinis M, Kashyap N, Hsiao A, Wilson FP, Curtis JP, Grant M, Velazquez EJ, Desai NR, Ahmad T. COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. PLOS ONE 2020, 15: e0238829. PMID: 32997657, PMCID: PMC7526909, DOI: 10.1371/journal.pone.0238829.Peer-Reviewed Original ResearchConceptsHeart failure patientsIntegrated health care systemHeart Failure RegistryHealth care systemFailure patientsCOVID-19 infectionCare systemCOVID-19SARS-CoV-2 infectionReal-time registryRenin-angiotensin blockersRetrospective chart reviewCoronary artery diseaseRisk of deathCOVID-19 testingAngiotensin blockersMultiple comorbiditiesRespiratory failureChart reviewSymptomatic patientsArtery diseaseHeart failureComorbid conditionsPatient mortalityClinical managementEvaluation of Case Volumes of a Heart Transplant Program and Short-term Outcomes After Changes in the United Network for Organ Sharing Donor Heart Allocation System
Mori M, Wilson L, Ali A, Ahmad T, Anwer M, Jacoby D, Geirsson A, Krumholz HM. Evaluation of Case Volumes of a Heart Transplant Program and Short-term Outcomes After Changes in the United Network for Organ Sharing Donor Heart Allocation System. JAMA Network Open 2020, 3: e2017513. PMID: 32945877, PMCID: PMC7501535, DOI: 10.1001/jamanetworkopen.2020.17513.Peer-Reviewed Original ResearchConceptsYale-New Haven HospitalHeart transplant programShort-term outcomesHeart transplantHeart transplant volumeNew Haven HospitalDonor heartsPatient selectionRecipient selectionTransplant programsTransplant volumeWaiting listCase volumeDonor heart allocation systemPre-post cohort studyConservative patient selectionUnused donor heartsHeart allocation systemHigher median numberCirculatory assist devicesCohort studyPatient characteristicsMore patientsSingle centerCenter volumeComparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation
Higgins AY, Bjerre J, Parzynski CS, Minges KE, Ahmad T, Desai NR, Enriquez A, Spatz ES, Friedman DJ, Curtis JP, Hlatky MA, Freeman JV. Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. The American Journal Of Cardiology 2020, 133: 116-125. PMID: 32862971, DOI: 10.1016/j.amjcard.2020.07.035.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationICM patientsIschemic cardiomyopathyNational Cardiovascular Data Registry ICD RegistryCox proportional hazards regression modelPrimary prevention ICD implantationLeft ventricular ejection fractionProportional hazards regression modelsPrimary prevention ICDsRetrospective cohort studyVentricular ejection fractionKaplan-Meier curvesHazards regression modelsRisk of mortalityComparison of mortalityMedian followCohort studyICD implantationEjection fractionHeart failureHospital readmissionICD RegistryPatient subgroups
2015
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, Freilich B, Zamparo J, Brown K, Dimitrova D, Kumar M, Manion D, Heath-Chiozzi M, Wolf R, Hughes E, Muir AJ, Hernandez AF. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015, 62: 409-416. PMID: 25251156, DOI: 10.1002/hep.27488.Peer-Reviewed Original ResearchConceptsNucleotide polymerase inhibitorLVEF dysfunctionPolymerase inhibitorsB-type natriuretic peptide levelsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionActing antiviral (DAA) agentsSevere myocyte damageC virus infectionNatriuretic peptide levelsPhase II studyVentricular ejection fractionT-wave inversionOff-target toxicityHCV treatmentHepatitis CII studySystolic functionTransthoracic echocardiogramEjection fractionNew DAAsCardiac dysfunctionElectrocardiogram changesPathological findingsCardiac toxicity